|Elimination half-life||70-80 min|
|Chemical and physical data|
|Molar mass||57647.3 g/mol|
|‹See TfM› (what is this?)|
Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these.
In 2014 marketing of Ontak was discontinued in the US.
- Turturro F (2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Rev Anticancer Ther. 7 (1): 11–7. doi:10.1586/14737126.96.36.199. PMID 17187516.
- FDA Page Last Updated: May 11, 2009 Changes in the Ontak (denileukin diftitiox) Package Insert to Include a Description of Ophthalmologic Adverse Events
- "FDA Drug Shortages". FDA. 31 January 2014. Retrieved 3 July 2017.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|